Prognostic Biomarkers for Patients with Early Stage Lung Cancer


Surgery is the standard care for patients with stage I lung cancer. Despite successful surgery, 20-30% of patients will relapse. Chemotherapy can improve patient survival; however, it is controversial if early stage cancer patients should be treated with chemotherapy since, for many cases, it will harm quality of life with little therapeutic benefit.

Utilizing patient samples, the investigators conducted a retrospective study in eight patient cohorts that validated the gene classifier set. These prognostic methods can guide physicians to select appropriate treatment and follow-up while sparing other patients of unnecessary treatment and negative side-effects of chemotherapy.



Potential Commercial Applications: Competitive Advantages:
  • Method to determine the prognosis of patients with lung cancer.
  • Method to select more effective treatment and post-operative follow-up for patients with early stage lung cancer.
 
  • Assays were validated in human tissue samples and eight different patient cohorts.


Development Stage:
Pre-clinical (in vivo)

Related Invention(s):
E-181-2006


Inventors:

Curtis Harris (NCI)  ➽ more inventions...

Aaron Schetter (NCI)  ➽ more inventions...

Ichiro Akagi (NCI)  ➽ more inventions...

Hirokazu Okayama (NCI)  ➽ more inventions...


Intellectual Property:
U.S. Pat: 2885425 issued 2017-07-26

Publications:
Ichiro Akagi et al. PMID 23639940

Collaboration Opportunity:

Licensing and research collaboration


Licensing Contact:
John Hewes, Ph.D.
Email: John.Hewes@nih.gov
Phone: 240-276-5515

OTT Reference No: E-048-2012
Updated: Apr 9, 2018